Clinical trial data suggest that first-line anti-PD-1 + anti-CTLA-4 combination therapy results in better survival rates in patients with BRAF V600 mutant metastatic melanoma than first-line BRAF + MEK inhibitor combination therapy [11,12]. This evidence concerns the gene BRAF and metastatic melanoma.